Search results
Showing 1 to 15 of 20 results for amyloidosis
Eplontersen for treating hereditary transthyretin-related amyloidosis [ID6337]
In development [GID-TA11392] Expected publication date: 27 November 2024
Inotersen for treating hereditary transthyretin amyloidosis (HST9)
Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis.
Patisiran for treating hereditary transthyretin amyloidosis (HST10)
Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy.
Vutrisiran for treating hereditary transthyretin-related amyloidosis (TA868)
Evidence-based recommendations on vutrisiran (Amvuttra) for treating hereditary transthyretin-related amyloidosis in adults.
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)
Evidence-based recommendations on tafamidis (Vyndaqel) for treating transthyretin amyloidosis with cardiomyopathy in adults.
Vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy [ID6470]
In development [GID-TA11598] Expected publication date: TBC
Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354]
Awaiting development [GID-TA11415] Expected publication date: TBC
Technology appraisal and highly specialised technologies appeals
Technology appraisal and Highly specialised technologies appeals
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy TSID 12015
Awaiting development [GID-TA11551] Expected publication date: TBC
CAEL-101 with standard care for untreated amyloid light chain amyloidosis TS ID 10666
Awaiting development [GID-TA11182] Expected publication date: TBC
Find out more about NICE's new proportionate approach to technology appraisals
This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.